Literature DB >> 17098846

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

D Grosset1, L Taurah, D J Burn, D MacMahon, A Forbes, K Turner, A Bowron, R Walker, L Findley, O Foster, K Patel, C Clough, B Castleton, S Smith, G Carey, T Murphy, J Hill, U Brechany, P McGee, S Reading, G Brand, L Kelly, K Breen, S Ford, M Baker, A Williams, J Hearne, N Qizilbash, K Ray Chaudhuri.   

Abstract

BACKGROUND: The issue of when to start treatment in Parkinson's disease (PD) remains controversial. Some favour treatment at diagnosis while others opt for a "wait and watch" policy. The effect of the latter policy on the self reported health status of people with PD is unknown. AIMS: To record self reported health status through longitudinal use of a validated PD specific questionnaire (PDQ-39) in untreated PD patients in multiple centres in the UK. To compare patients who were left untreated with those who were offered treatment during follow-up.
METHODS: A multicentre, prospective, "real life" observational audit based study addressing patient reported outcomes in relation to self reported health status and other sociodemographic details.
RESULTS: 198 untreated PD were assessed over a mean period of 18 months. During two follow-up assessments, the self reported health status scores in all eight domains of the PDQ-39 and the overall PDQ-39 summary index worsened significantly (p<0.01) in patients left untreated. In a comparative group in whom treatment was initiated at or soon after diagnosis, there was a trend towards improvement in self reported health status scores after treatment was started.
CONCLUSIONS: This study addresses for the first time self reported health status, an indicator of health related quality of life, in untreated PD. The findings may strengthen the call for re-evaluation of the policy to delay treatment in newly diagnosed patients with PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17098846      PMCID: PMC2117846          DOI: 10.1136/jnnp.2006.098327

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Authors:  C W Olanow; R L Watts; W C Koller
Journal:  Neurology       Date:  2001-06       Impact factor: 9.910

Review 2.  Measuring motor complications in clinical trials for early Parkinson's disease.

Authors:  C Marras; A E Lang
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

Review 3.  Dopamine agonist monotherapy in Parkinson's disease.

Authors:  C E Clarke; M Guttman
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

4.  Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire.

Authors:  V Peto; C Jenkinson; R Fitzpatrick
Journal:  Age Ageing       Date:  2001-07       Impact factor: 10.668

5.  The EQ-5D--a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease.

Authors:  A Schrag; C Selai; M Jahanshahi; N P Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

6.  Factors impacting on quality of life in Parkinson's disease: results from an international survey.

Authors: 
Journal:  Mov Disord       Date:  2002-01       Impact factor: 10.338

7.  Development and testing of the Parkinson's disease quality of life scale.

Authors:  Mickie Welsh; Michael P McDermott; Robert G Holloway; Sandy Plumb; Ronald Pfeiffer; Jean Hubble
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Authors:  Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts
Journal:  Arch Neurol       Date:  2004-07

Review 9.  The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.

Authors: 
Journal:  Mov Disord       Date:  2003-07       Impact factor: 10.338

10.  Slowing Parkinson's disease progression: recent dopamine agonist trials.

Authors:  Erwin B Montgomery
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

View more
  29 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

Review 2.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

3.  Improving symptom control in early Parkinson's disease.

Authors:  Stuart H Isaacson; Robert A Hauser
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

4.  Self-reported health in people with Parkinson's disease left untreated at diagnosis.

Authors:  Peter Hagell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-29       Impact factor: 10.154

Review 5.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 6.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

Review 7.  Early Parkinson's disease and non-motor issues.

Authors:  K Ray Chaudhuri; Yogini Naidu
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

8.  Update on the diagnosis and management of Parkinson's disease.

Authors:  Christopher Kobylecki
Journal:  Clin Med (Lond)       Date:  2020-07       Impact factor: 2.659

9.  Treatment disparities in Parkinson's disease.

Authors:  Nabila Dahodwala; Ming Xie; Elizabeth Noll; Andrew Siderowf; David S Mandell
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

10.  Earlier Dopaminergic Treatment in Parkinson's Disease Is Not Associated With Improved Outcomes.

Authors:  Ruth B Schneider; Xiang Lu; Kevin Biglan; Michael P McDermott
Journal:  Mov Disord Clin Pract       Date:  2019-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.